Advanced search
1 file | 60.23 KB Add to list

An assessement of the cost-effectiveness of escitalopram versus multiple comparators as first line antidepressant in patients with major depressive disorder (MDD) in Belgium

(2012) VALUE IN HEALTH. 15(7). p.A338-A338
Author
Organization

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 60.23 KB

Citation

Please use this url to cite or link to this publication:

MLA
Druais, S, A Gauthier, K Demyttenaere, et al. “An Assessement of the Cost-effectiveness of Escitalopram Versus Multiple Comparators as First Line Antidepressant in Patients with Major Depressive Disorder (MDD) in Belgium.” Value in Health. Vol. 15. 2012. A338–A338. Print.
APA
Druais, S., Gauthier, A., Demyttenaere, K., Brignone, M., De Pauw, A., Defraigne, G., & Annemans, L. (2012). An assessement of the cost-effectiveness of escitalopram versus multiple comparators as first line antidepressant in patients with major depressive disorder (MDD) in Belgium. VALUE IN HEALTH (Vol. 15, pp. A338–A338). Presented at the ISPOR 17th Annual International Meeting.
Chicago author-date
Druais, S, A Gauthier, K Demyttenaere, M Brignone, A De Pauw, G Defraigne, and Lieven Annemans. 2012. “An Assessement of the Cost-effectiveness of Escitalopram Versus Multiple Comparators as First Line Antidepressant in Patients with Major Depressive Disorder (MDD) in Belgium.” In Value in Health, 15:A338–A338.
Chicago author-date (all authors)
Druais, S, A Gauthier, K Demyttenaere, M Brignone, A De Pauw, G Defraigne, and Lieven Annemans. 2012. “An Assessement of the Cost-effectiveness of Escitalopram Versus Multiple Comparators as First Line Antidepressant in Patients with Major Depressive Disorder (MDD) in Belgium.” In Value in Health, 15:A338–A338.
Vancouver
1.
Druais S, Gauthier A, Demyttenaere K, Brignone M, De Pauw A, Defraigne G, et al. An assessement of the cost-effectiveness of escitalopram versus multiple comparators as first line antidepressant in patients with major depressive disorder (MDD) in Belgium. VALUE IN HEALTH. 2012. p. A338–A338.
IEEE
[1]
S. Druais et al., “An assessement of the cost-effectiveness of escitalopram versus multiple comparators as first line antidepressant in patients with major depressive disorder (MDD) in Belgium,” in VALUE IN HEALTH, Washington, DC, USA, 2012, vol. 15, no. 7, pp. A338–A338.
@inproceedings{3136130,
  articleno    = {abstract PMH25},
  author       = {Druais, S and Gauthier, A and Demyttenaere, K and Brignone, M and De Pauw, A and Defraigne, G and Annemans, Lieven},
  booktitle    = {VALUE IN HEALTH},
  issn         = {1098-3015},
  language     = {eng},
  location     = {Washington, DC, USA},
  number       = {7},
  pages        = {abstract PMH25:A338--abstract PMH25:A338},
  title        = {An assessement of the cost-effectiveness of escitalopram versus multiple comparators as first line antidepressant in patients with major depressive disorder (MDD) in Belgium},
  volume       = {15},
  year         = {2012},
}

Web of Science
Times cited: